Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glucose metabolism disorders (incl diabetes mellitus)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Glucose metabolism disorders (incl diabetes mellitus). Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-000619-10 Sponsor Protocol Number: RUNMC-EX-BCM-2012 Start Date*: 2012-07-24
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4
    Medical condition: patients with long-standing type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005599-27 Sponsor Protocol Number: ABR51980 Start Date*: 2016-12-07
    Sponsor Name:Radboud University Medical Center Nijmegen
    Full Title: Visualizing beta cells in morbid obese patients with T2D before and after bariatric surgery (NL51980.091.15)
    Medical condition: Diabetes Type 2, bariatric surgery, morbid obesitas
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    19.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003006-33 Sponsor Protocol Number: RUNMC-GLP1-EX-GELO-2014 Start Date*: 2015-02-16
    Sponsor Name:Radboud University Medical Center
    Full Title: Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 uptake in the kidney
    Medical condition: The aim of this study is to reduce the kidney uptake during 111In-DTPA- exendin4 imaging, a promising and valuable tool for beta-cell mass imaging and quantification, which can be applied in patien...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    17.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    17.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    17.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000821-35 Sponsor Protocol Number: RUNMC-GLP1-TRANSPL-2015 Start Date*: 2015-09-22
    Sponsor Name:Radboud University Medical Center
    Full Title: Visualizing beta cells after Intrahepatic Islet of Langerhans Transplantation
    Medical condition: Intrahepatic islet transplantation in type 1 diabetes patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    18.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    18.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004683-38 Sponsor Protocol Number: G113 Start Date*: 2015-01-26
    Sponsor Name:Fondazione per il Tuo cuore onlus-ANMCO
    Full Title: Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry.
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    17.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    17.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003968-20 Sponsor Protocol Number: MEX0114 Start Date*: 2015-10-08
    Sponsor Name:Dompé farmaceutici s.p.a.
    Full Title: A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes
    Medical condition: new onset type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    18.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    18.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    18.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002590-73 Sponsor Protocol Number: 901 Start Date*: 2005-11-14
    Sponsor Name:Andromeda Biotech Ltd.
    Full Title: A phase III, multinational, randomised, double-blind, placebo-controlled, parallel-group study to investigate the clinical efficacy and safety of Diapep277 in newly diagnosed type I Diabetes patients.
    Medical condition: Type I Diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) ES (Completed) AT (Completed) GB (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022718-17 Sponsor Protocol Number: 1245.31 Start Date*: 2011-03-15
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed) SK (Completed) SI (Completed) BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004317-90 Sponsor Protocol Number: NL51058.091.14 Start Date*: 2015-02-25
    Sponsor Name:Radboud University Medical Center Nijmegen
    Full Title: Visualizing beta cells in patients with remission of T2DM after bariatric surgery
    Medical condition: Patients with Type 2 Diabetes, with or without remission after bariatric surgery
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    17.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    17.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022658-18 Sponsor Protocol Number: CLAF237A23150 Start Date*: 2011-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) BG (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-005220-33 Sponsor Protocol Number: D1690C00004 Start Date*: 2008-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapaglif...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000436-74 Sponsor Protocol Number: 432 Start Date*: 2007-11-27
    Sponsor Name:Poissy Hospital
    Full Title: Impact of two glucose control regimens by insulin on hospital mortality in intensive care unit patients (INSUREA Study)
    Medical condition: hyperglycemia in critical care unit patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003049-16 Sponsor Protocol Number: CL007_140 Start Date*: 2011-08-29
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus, nephropathy, albuminuria
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.0 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    14.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    14.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003626-24 Sponsor Protocol Number: MK-3102-011 Start Date*: 2013-01-25
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) NL (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000393-29 Sponsor Protocol Number: 69HCL18_0047 Start Date*: 2018-07-04
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Dulaglutide And Insulin MicrosecretiON in type I Diabetes - DIAMOND
    Medical condition: Adult patients with Type 1 Diabètes (T1D)> 4years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000031-26 Sponsor Protocol Number: R256918DIA2001 Start Date*: 2007-12-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) NL (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013881-25 Sponsor Protocol Number: 1941-CL-0005 Start Date*: 2010-03-18
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment with ASP1941 in Com...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002794-51 Sponsor Protocol Number: CLMF237A2302 including amd 2 Start Date*: 2006-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, active-controlled, multicentre study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monothe...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-006162-40 Sponsor Protocol Number: NODAT-BELATAC Start Date*: 2013-05-28
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
    Full Title: NEW-ONSET DIABETES MELLITUS AFTER RENAL TRANSPLANTATION. A MULTICENTRE, PROSPECTIVE, RANDOMIZED, OPEN STUDY TO EVALUATE BELATACEPT-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSION
    Medical condition: Adult kidney transplant recipients older than 45 years old with risk of developing prediabetes states after renal transplantation (PREDAT) and diabetes mellitus after renal transplantation (NODAT)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    15.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003963-31 Sponsor Protocol Number: BEGAMI Start Date*: 2007-11-19
    Sponsor Name:Karolinska Institutet
    Full Title: A three months, double-blind, randomized, parallell-group study evaluating the efficacy of sitagliptin (Januvia®) versus placebo on beta-cell function in patients with newly detected glucose abnorm...
    Medical condition: Patients with acute myocardial infarction or unstable angina pectoris and newly detected impaired glucose tolerance or type 2 diabetes (without any previous pharmacological glucose-lowering treatment)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    9.1 10051592 Acute coronary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:38:42 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA